Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in failure to induce global or clinical improvement compared with SASP (high certainty).
1 finding from 1 review
Failure to maintain remission · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in failure to maintain clinical remission compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission
Ustekinumab probably leads to lower failure to maintain clinical response compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to maintain remission · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in failure to maintain clinical remission compared with placebo (low certainty).
1 finding from 1 review
Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in failure to maintain clinical response compared with placebo (low certainty).
1 finding from 1 review
Lack of symptom control · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
On‐demand deprescribing may leads to higher lack of symptom control compared with continued use (low certainty).
1 finding from 1 review
Pill use (pills/week) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
1 finding from 1 review
Use of healthcare resources (cost effectiveness, time taken to fit, number of dental visits) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug withdrawal events ‐ esophagitis (endoscopic findings) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
On‐demand deprescribing may leads to higher adverse drug withdrawal events ‐ esophagitis (endoscopic findings) compared with continued use (low certainty).
1 finding from 1 review
Participant satisfaction · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
It is very uncertain whether on‐demand deprescribing changes participant satisfaction compared with continued use (very low certainty).
1 finding from 1 review
Lack of symptom control · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)
It is very uncertain whether abrupt discontinuation deprescribing changes lack of symptom control compared with continued use (very low certainty).
1 finding from 1 review
Adverse drug withdrawal events ‐ relapse (endoscopic findings) · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)
It is very uncertain whether abrupt discontinuation deprescribing changes adverse drug withdrawal events ‐ relapse (endoscopic findings) compared with continued use (very low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower failure to induce clinical response compared with placebo (moderate certainty).
1 finding from 1 review